Lupin, Inc.

Lupin Atlantis Holdings Sa

Prathap Sreedharan Nair

Rajender Kumar Kamboj

Venkata Poornapragnacharyulu Palle

Milind Dattatraya Sindkhedkar

Mahadeo Bhaskar Tryambake

Chetan Sanjay Pawar

Ganesh Bhausaheb Gudade

Sanjeev Anant Kulkarni

Anil Kashiram Hajare

Chaitanya Prabhakar Kulkarni

Dipak Raychand Lagad

Sachin Sethi

Neelima Sinha

Sudershan Kumar Arora

Rajan Goel

Balasaheb Arjun Gore

Vijaykumar Jagdishwar Patil

Navnath Popat Karche

Manojkumar Ramprasad Shukla

Samiron Phukan

Rakesh Kumar Sinha

Nilesh Raghunath Khedkar

Shankar Ajay

Majid Bashir Sayyed

Pradeep Rangrao Patil

Pradip Balu Wagh

Sudhakar Maruti Balgude

Ganesh Kakade

Nabendu Saha

Vikas Sitaram Tambe

Sai Kumar Chakka

Azmi Reddy

Pravin Patil

K H Sreedhara Swamy

Prasad Purushottam Dixit

Dagadu Dube

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, Formula (I) wherein, ring A, Rto R, X, Y, m, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

Substituted tricyclic compounds

The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

PRMT5 inhibitors

The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors

The invention relates to naphthalene compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium sensing receptor modulators (Ca SR). The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium sensing receptor modulators (Ca SR) channel modulators.

Substituted naphthalene compounds as calcium sensing receptor modulators

The present invention is related to novel 2-Amino-2-[8-(dimethyl carbamoyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-exo-ethanoyl derivatives of the general formula (A), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved. 

[object Object]

The present invention is related to novel compounds of the general formula A, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved.

Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors

Novel compounds belonging to the class of oxazolidinones possessing potent antimycobacterial properties especially useful in the treatment of acid fast organisms such as-intracellular complex,and. The compound and its pharmaceutically acceptable salts act as antibacterial agents. Also mentioned is a method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial conditions such as, drug resistant-intracellular complex,and., including administering an antimycobacterially effective amount of the compound and/or pharmaceutically acceptable salts. There is also mentioned a process for the manufacture of the compound or its pharmaceutically acceptable salts.

Antimycobacterial compounds

Growing community of inventors

Maharashtra, India

Prathap Sreedharan Nair